Partial
Mostly Aligned
Patient Risk:
Low
Summary
Only one interaction-related statement in the provided excerpt (“No formal drug interaction studies…”) is directly supported; the other claims are not supported by the supplied label text and include content about generic availability/authorized generics/patents that is not addressed in the excerpt.
Category Scores
Accurate Statements
No formal drug interaction studies have been performed with AIRSUPRA.
Section 7 DRUG INTERACTIONS: “No formal drug interaction studies have been performed with AIRSUPRA.”
Any specific interaction claim cannot be verified against FDA-approved labeling from the supplied content because the provided label excerpt only states that no formal drug interaction studies were performed.
Section 7 DRUG INTERACTIONS excerpt provided only contains the “No formal drug interaction studies…” sentence; no other interaction statements are included in the supplied text.
Unsupported Statements
Airsupra (albuterol/budesonide inhalation) does not have a fully approved generic available based on the information provided here.
The supplied label excerpt contains no information about generic availability or whether an approved generic exists.
Generic versions of Airsupra typically become possible only after patent and regulatory exclusivity barriers expire or are cleared through a legal/regulatory pathway.
The supplied label excerpt does not discuss patents, exclusivity, or regulatory pathways for generics.
The timing for a generic Airsupra to become available depends on the specific patents and any exclusivity listed for Airsupra.
The supplied label excerpt does not mention patents or exclusivity for Airsupra.
To find an “Airsupra generic,” one should check for an FDA-approved generic with the same active ingredients and route of administration.
The supplied label excerpt does not provide guidance on how to identify generics.
One should also check for an authorized generic, defined as being sold under a different label but still marketed as an approved product.
The supplied label excerpt does not mention authorized generics or provide definitions/guidance.
One should also check for a non-identical “similar” product, which is not a generic and may not be interchangeable.
The supplied label excerpt does not discuss “similar” products, interchangeability, or substitution criteria.
Contradictions
Important Omissions
If the intent was to address drug interactions, the label excerpt only states that no formal interaction studies were performed; the AI-generated content does not provide any additional interaction information that could be supported by other provided label sections (none were provided).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-supported safety-relevant statement provided is that no formal interaction studies were performed. The other claims are about generic availability and are not directly tied to labeled safety warnings/precautions in the supplied excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims about generic availability, patents/exclusivity timing, authorized generics, and “similar” products are not supported by the provided label text.
Suggested Improvement
Limit label-based conclusions to statements actually present in the supplied prescribing information (e.g., “No formal drug interaction studies…” in Section 7), and avoid making assertions about generic/authorized generic availability unless those details are present in the provided FDA-approved label content.